Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BerGenBio ASA ( (BRRGF) ) has provided an update.
Oncoinvent ASA has announced the outcomes of an extraordinary general meeting held electronically on 8 January 2026, at which shareholders approved an audited interim balance sheet, a reverse share split, a capital reduction and new authorizations for the Board of Directors. These corporate actions collectively signal a significant restructuring of the company’s capital structure, potentially improving share tradability and providing the board with greater flexibility for future financing or strategic initiatives, with implications for existing shareholders and the company’s positioning in the competitive radiopharmaceuticals market.
More about BerGenBio ASA
Oncoinvent ASA is a clinical-stage biotechnology company specializing in novel radiopharmaceutical cancer therapies. Its lead product candidate, Radspherin®, is an investigational alpha-emitting radium-224 therapy designed to target micro-metastases after surgery, particularly in peritoneal carcinomatosis from ovarian and colorectal cancers. The company operates a state-of-the-art manufacturing facility in Oslo, employs around 40 staff, is listed on the Oslo Stock Exchange, and is advancing Radspherin® through a clinical program that includes completed Phase 1 and Phase 1/2a trials and an ongoing randomized Phase 2 trial in the US, UK and Europe, with encouraging early efficacy and no serious safety concerns reported to date.
Average Trading Volume: 1,321,950
Current Market Cap: NOK212.3M
See more data about BRRGF stock on TipRanks’ Stock Analysis page.